Nuvectis Loss Balloons To $30.1 Million On A $20.0 Million License Payment For Two Haisco Drugs
The drug developer holds $140.7 million in cash and says it can fund operations into the second half of 2029.
Nuvectis Pharma, a clinical-stage biotech, reported a third-quarter net loss of $30.1 million, up from $7.5 million a year earlier, driven by a $20.0 million upfront payment to license two drugs from Haisco Pharmaceutical Group. The company said Wednesday it expects an FDA update on the U.S. path for ciprocopan, its lead drug, before year-end.
Strip out the one-time items
The loss includes the $20.0 million license payment for NXP100 and NXP200, plus $1.8 million in milestones tied to NXP900, the company said in its earnings release. Excluding those and $2.4 million of non-cash stock compensation, the third-quarter loss was $5.8 million. On a per-share basis the full loss was $1.02, against $0.44 a year earlier.
Research and development spending rose to $27.4 million from $5.8 million. General and administrative costs rose to $3.7 million from $2.0 million, mostly on a $1.2 million increase in professional and consulting services. For the first nine months, the net loss was $43.1 million, compared with $19.1 million a year earlier.
Cash up more than fourfold
Cash and equivalents reached $140.7 million on September 30, against $31.6 million at the end of 2025. In July the company raised $115.0 million in gross proceeds in a follow-on offering, and another $39.5 million through its existing at-the-market program, $37.0 million of it placed with a single healthcare-focused fund.
Chief Executive Ron Bentsur called it "the strongest financial position in Nuvectis' history" and said the money should fund operations "into the second half of 2029."
A pivot toward complement drugs
Nuvectis had been an oncology-focused developer. The Haisco deal added ex-China rights to ciprocopan (NXP100), a once-daily oral Complement Factor B inhibitor that China approved in July for patients with paroxysmal nocturnal hemoglobinuria, a blood disorder, who have not had complement inhibitors. A second Chinese application, for patients previously treated with anti-C5 therapy, is under review, with approval expected in the first quarter of 2027.
The company also holds NXP200, a BRAF inhibitor. In expanded early-stage data presented at the ESMO congress in October, 40.0% of high-grade glioma patients responded, and 87.5% of those responders achieved tumor reductions above 80%. NXP900, which blocks SRC and YES1 enzymes, is in early-stage combination trials; an update in lung cancer is expected in the first half of 2027.
Year-end milestones
Before year-end, Nuvectis expects an FDA update on whether the China data package can support a U.S. marketing application for ciprocopan in PNH. It also plans U.S. IND submissions, the filings that allow human trials in the U.S., for NXP100 in an indication beyond PNH and for NXP200.
In September the company hired Dustin Little, M.D., a former AstraZeneca clinical executive, as senior vice president and head of its complement program.
NXP200 data from China are due in early 2027, and the company expects ciprocopan's FDA update by year-end.